IRAK4 and Alzheimer disease: In patients with AD, we did observe a trend in downregulation of IL-1α, COX2, OX40, CXCL13 and IL27RA, further supporting that the inflammation in AD is pleiotropic and that IRAK4 targeting may be capable of modifying the disease by impacting novel pathways.